Rectal Cancers

CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.

Despite being considered a fairly rare disease, the incidence of anal cancer has doubled over the last 30 years, with the American Cancer Society estimating approximately 10,540 new cases and 2,190 related deaths in 2024.